The approval of patents for PMN310 in multiple jurisdictions significantly strengthens ProMIS Neurosciences' global intellectual property position. This development is likely to positively impact investor confidence and the company's valuation in the short term, as it solidifies the company's competitive edge in the Alzheimer's treatment market. The focus on a novel target, toxic oligomers of amyloid-beta, which is a major driver of Alzheimer's disease, highlights the potential of PMN310 to meet a critical unmet medical need.